Akarna Therapeutics
Gilead and PAHO announce milestone partnership to accelerate access to HIV pre-exposure treatment
The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean
Gilead opens new research centre bringing together oncology, inflammation and research data science teams
The centre in California supports the company’s $32bn US investment
Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring
Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health
Roche to acquire 89bio in a deal worth up to US$3.5bn
With the agreement, Roche will gain a treatment for moderate to severe MASH
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use
An estimated 1.2 million people in the US are currently living with the virus
Gilead Sciences and Kymera enter oncology partnership worth up to $750m
The companies will focus on advancing Kymera’s oral molecular glue degrader programme
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
More than 100 people in the US were diagnosed with HIV every day in 2023
GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn
Steatotic liver disease affects approximately 5% of the global population
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
The drug has already been approved in the US to treat patients with non-cirrhotic MASH
Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis
The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease
Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC
Primary biliary cholangitis affects approximately 163,000 people in Europe
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
The company gained access to the drug through its $4.3bn acquisition of CymaBay